Literature DB >> 25540722

Pharmacological management of behavioral symptoms associated with dementia.

Subramoniam Madhusoodanan1, Mark Bryan Ting1.   

Abstract

Dementia is a clinical syndrome with features of neurocognitive decline. Subtypes of dementia include Alzheimer's, frontotemporal, Parkinson's, Lewy body disease, and vascular type. Dementia is associated with a variety of neuropsychiatric symptoms that may include agitation, psychosis, depression, and apathy. These symptoms can lead to dangerousness to self or others and are the main source for caregiver burnout. Treatment of these symptoms consists of nonpharmacological and pharmacological interventions. However, there are no Food and Drug Administration-approved medications for the treatment of behavioral and psychological symptoms of dementia. Pharmacological interventions are used off-label. This article reviews the current evidence supporting or negating the use of psychotropic medications along with safety concerns, monitoring, regulations, and recommendations.

Entities:  

Keywords:  Alzheimer’s disease; Antipsychotics; Dementia; Pharmacological management; Psychotropics

Year:  2014        PMID: 25540722      PMCID: PMC4274589          DOI: 10.5498/wjp.v4.i4.72

Source DB:  PubMed          Journal:  World J Psychiatry        ISSN: 2220-3206


  42 in total

1.  Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome.

Authors:  D V Jeste; S I Finkel
Journal:  Am J Geriatr Psychiatry       Date:  2000       Impact factor: 4.105

Review 2.  Introduction: antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric patients.

Authors:  S Madhusoodanan
Journal:  Am J Geriatr Psychiatry       Date:  2001       Impact factor: 4.105

3.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

4.  Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Pierre N Tariot; Lon Schneider; Ira R Katz; Jacobo E Mintzer; Jamie Street; Margaret Copenhaver; Celeste Williams-Hughes
Journal:  Am J Geriatr Psychiatry       Date:  2006-08-11       Impact factor: 4.105

5.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

Review 6.  Safety of benzodiazepines in the geriatric population.

Authors:  Subramoniam Madhusoodanan; Olivera J Bogunovic
Journal:  Expert Opin Drug Saf       Date:  2004-09       Impact factor: 4.250

7.  Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Authors:  D P Devanand; Jacobo Mintzer; Susan K Schultz; Howard F Andrews; David L Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Bruce Levin
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

Review 8.  Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach?

Authors:  Subramoniam Madhusoodanan; Payal Shah; Ronald Brenner; Sanjay Gupta
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Authors:  Clive Ballard; Maria Luisa Hanney; Megan Theodoulou; Simon Douglas; Rupert McShane; Katja Kossakowski; Randeep Gill; Edmund Juszczak; Ly-Mee Yu; Robin Jacoby
Journal:  Lancet Neurol       Date:  2009-01-08       Impact factor: 44.182

10.  The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study.

Authors:  Sibel Cakir; Isin Baral Kulaksizoglu
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more
  9 in total

1.  Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.

Authors:  Rajesh R Tampi; Deena J Tampi; Silpa Balachandran; Shilpa Srinivasan
Journal:  Ther Adv Chronic Dis       Date:  2016-07-15       Impact factor: 5.091

2.  Treatment and Management of Dementia Due to Alzheimer's Disease.

Authors:  Jennifer Rose V Molano; Robin Bratt; Rhonna Shatz
Journal:  Curr Treat Options Neurol       Date:  2015-08       Impact factor: 3.598

3.  Neuroprotective Effects of the Herbal Formula B401 in Both Cell and Mouse Models of Alzheimer's Disease.

Authors:  Chih-Hsiang Hsu; Sheue-Er Wang; Ching-Lung Lin; Chun-Jen Hsiao; Shuenn-Jyi Sheu; Chung-Hsin Wu
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-28       Impact factor: 2.629

4.  Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline.

Authors:  Marie Turmo Lornstad; Marte Aarøen; Sverre Bergh; Jūratė Šaltytė Benth; Anne-Sofie Helvik
Journal:  BMC Geriatr       Date:  2019-04-25       Impact factor: 3.921

5.  Creating a toolkit with stakeholders for leveraging tablet computers to support person-centred dementia care in hospitals.

Authors:  John Shadarevian; Cheryl Chan; Annette Berndt; Cathy Son; Mario Gregorio; Neil Horne; Jim Mann; Christine Wallsworth; Bryan Chow; Ryan O'Neill; Lillian Hung
Journal:  J Rehabil Assist Technol Eng       Date:  2020-11-23

6.  Development of Synergy-Based Combination for Learning and Memory Using in vitro, in vivo and TLC-MS-Bioautographic Studies.

Authors:  Maaz Ahmed Khan; Varsha Srivastava; Mariya Kabir; Monalisha Samal; Areeba Insaf; Mohammad Ibrahim; Sultan Zahiruddin; Sayeed Ahmad
Journal:  Front Pharmacol       Date:  2021-07-02       Impact factor: 5.810

7.  ADMA and NT pro-BNP are associated with overall mortality in elderly.

Authors:  Safoura Sheikh Rezaei; Stefan Weisshaar; Brigitte Litschauer; Ghazaleh Gouya; Gerald Ohrenberger; Michael Wolzt
Journal:  Eur J Clin Invest       Date:  2018-11-16       Impact factor: 4.686

8.  Quetiapine and novel PDE10A inhibitors potentiate the anti-BuChE activity of donepezil.

Authors:  Joanna Sikora; Maria Podsiedlik; Tadeusz Pietras; Marcin Kosmalski; Mikołaj Matłoka; Rafał Moszczyński-Petkowski; Maciej Wieczorek; Magdalena Markowicz-Piasecka
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

9.  Predicting the Severity of Parkinson's Disease Dementia by Assessing the Neuropsychiatric Symptoms with an SVM Regression Model.

Authors:  Haewon Byeon
Journal:  Int J Environ Res Public Health       Date:  2021-03-04       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.